CN106036135A - 一种防止结石、快速排结石的药物、组合物、兽药 - Google Patents
一种防止结石、快速排结石的药物、组合物、兽药 Download PDFInfo
- Publication number
- CN106036135A CN106036135A CN201610434844.6A CN201610434844A CN106036135A CN 106036135 A CN106036135 A CN 106036135A CN 201610434844 A CN201610434844 A CN 201610434844A CN 106036135 A CN106036135 A CN 106036135A
- Authority
- CN
- China
- Prior art keywords
- calculus
- medicine
- item
- composition
- ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 239000000203 mixture Substances 0.000 title claims abstract description 16
- 238000007599 discharging Methods 0.000 title abstract description 5
- 229940079593 drug Drugs 0.000 title 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229960003459 allopurinol Drugs 0.000 claims abstract description 11
- 229960005336 magnesium citrate Drugs 0.000 claims abstract description 10
- 239000004337 magnesium citrate Substances 0.000 claims abstract description 10
- 235000002538 magnesium citrate Nutrition 0.000 claims abstract description 10
- 229960000206 potassium canrenoate Drugs 0.000 claims abstract description 10
- JTZQCHFUGHIPDF-RYVBEKKQSA-M potassium canrenoate Chemical compound [K+].O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@](CC4)(O)CCC([O-])=O)[C@@H]4[C@@H]3C=CC2=C1 JTZQCHFUGHIPDF-RYVBEKKQSA-M 0.000 claims abstract description 10
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims abstract description 10
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960003199 etacrynic acid Drugs 0.000 claims abstract description 8
- 239000005018 casein Substances 0.000 claims abstract description 7
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000021240 caseins Nutrition 0.000 claims abstract description 7
- 235000013372 meat Nutrition 0.000 claims abstract description 7
- 235000013336 milk Nutrition 0.000 claims abstract description 7
- 239000008267 milk Substances 0.000 claims abstract description 7
- 210000004080 milk Anatomy 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 7
- 239000000273 veterinary drug Substances 0.000 claims description 9
- 101100381997 Danio rerio tbc1d32 gene Proteins 0.000 claims description 6
- 101100381999 Mus musculus Tbc1d32 gene Proteins 0.000 claims description 6
- 235000013305 food Nutrition 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 208000009911 Urinary Calculi Diseases 0.000 abstract description 5
- 230000015572 biosynthetic process Effects 0.000 abstract description 5
- 239000008157 edible vegetable oil Substances 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract 8
- JSUAJTLKVREZHV-UHFFFAOYSA-N 1-[4-(1-pyrrolidinyl)but-2-ynyl]pyrrolidine Chemical compound C1CCCN1CC#CCN1CCCC1 JSUAJTLKVREZHV-UHFFFAOYSA-N 0.000 abstract 1
- 241000209761 Avena Species 0.000 abstract 1
- 235000007319 Avena orientalis Nutrition 0.000 abstract 1
- 235000021336 beef liver Nutrition 0.000 abstract 1
- 241000282326 Felis catus Species 0.000 description 25
- 210000002700 urine Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 10
- 239000003674 animal food additive Substances 0.000 description 9
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 7
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 7
- 229940116269 uric acid Drugs 0.000 description 7
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 230000036506 anxiety Effects 0.000 description 6
- 235000014590 basal diet Nutrition 0.000 description 6
- 230000029087 digestion Effects 0.000 description 5
- 230000027939 micturition Effects 0.000 description 5
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 4
- 230000036528 appetite Effects 0.000 description 4
- 235000019789 appetite Nutrition 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 208000010717 cat disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- CJRJTCMSQLEPFQ-UHFFFAOYSA-N 6-cat Chemical compound ClC1=CC=C2CC(N)CCC2=C1 CJRJTCMSQLEPFQ-UHFFFAOYSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002272 anti-calculus Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一种防止结石、快速排结石的药物、组合物、兽药,属于药物领域。其特征在于由A项和B项组成,A项按重量百分含量计由下述组分组成:别嘌呤醇15‑30%、乳酶生35‑50%、柠檬酸镁20‑40%、依他尼酸0.2‑1%、坎利酸钾0.5‑3%;B项按重量份由下述组分组成:酪蛋白50g、奶粉50g、牛肝200g、肉类200g、燕麦300g、食用油50g;将3克A项和B项混合,即可。本发明具有快速溶解尿路结石、防止尿路结石的形成、促进结石排出的功效。
Description
本申请是 2014103582930号专利的分案申请,原申请的申请日 2014-07-25 ,申请号是2014103582930 ,发明创造名称:一种防尿路结石的饲料添加剂。
技术领域
本发明涉及一种药物,具体地说,涉及一种防止结石、快速排结石的药物、组合物、兽药。
背景技术
现在很多家庭都养有犬、猫作为宠物,犬猫尿路结石病经常困扰着爱宠人士。尿路结石病是由尿中的尿酸和无机盐类析出形成结石,引起尿路粘膜发炎、出血和排尿障碍的疾病。犬、猫患尿结石之后有很多行为表现,包括频繁上厕所,每次尿量少,尿的时候比较痛苦需要长时间摆姿势,尿中会带有血色,经常舔私处,常常情绪不好,尤其是在上厕所前后比较焦虑。结石会堵塞犬、猫的尿道,导致犬、猫闭尿,当发生这种情况时,需要马上到宠物医院请医生为犬、猫导尿,因为12小时不排尿会引发肾衰,18小时不排尿会出现尿毒症,超过24小时就很有可能将膀胱憋爆,导致大出血死亡。目前对尿路结石均采用手术和服药治疗,能够防治尿路结石的兽药几乎没有,因此需要一种兽药,防止形成尿路结石、促进排出尿路结石,使宠物健康生长。
发明内容
本发明的目的在于提供一种防止结石、快速排结石的药物、组合物、兽药,具有防止尿路结石的形成、促进结石排出的功效,并且可以促消化,有利于宠物健康生长。
本发明的技术方案是:
一种防止结石、快速排结石的药物、组合物、兽药, 其特征在于由A项和B项组成,
A项按重量百分含量计由下述组分组成:别嘌呤醇15-30%、乳酶生35-50%、柠檬酸镁20-40%、依他尼酸0.2-1%、坎利酸钾0.5-3%;
B项按重量份由下述组分组成:酪蛋白50g、奶粉50g、牛肝200g、肉类200g、燕麦300g、食用油50g;
将3克A项和 B项混合,即可。
本发明进一步优选为:
一种防止结石、快速排结石的药物、组合物、兽药, 其特征在于由A项和B项组成,
A项按重量百分含量计由下述组分组成:别嘌呤醇21.5%、乳酶生35%、柠檬酸镁40%、依他尼酸0.7%、坎利酸钾2.8%;
B项按重量份由下述组分组成:酪蛋白50g、奶粉50g、牛肝200g、肉类200g、燕麦300g、食用油50g;
将3克A项和 B项混合,即可。
别嘌呤醇是黄嘌呤氧化酶抑制剂,阻断次黄嘌呤向黄嘌呤及黄嘌呤向尿酸的转化过程,别嘌呤醇的另一作用方式是抑制核苷酸合成,最终导致尿酸生成减少。乳酶生在本配方中用于肠内异常发酵,促进排泄有利于排出结石,防止结石聚集在体内,利于宠物健康生长。柠檬酸镁提供柠檬酸根离子和镁离子,柠檬酸根离子是一种很强的钙离子螯合剂,其和钙离子形成稳定而易溶于水的柠檬酸钙从尿中排出,同时镁离子可以抑制钙离子聚集,防止钙结石生长。依他尼酸是快速利尿剂,能够快速起到利尿效果,加速尿酸和结石排出,口服后吸收迅速,30分钟内出现作用,约2小时达最高峰,持续6~8小时。坎利酸钾具有慢性利尿作用,柔和的促使尿酸和结石排出。本配方配伍合理,各组分相辅相成,促进疗效发挥。
本发明的有益效果是:通过阻止尿酸的形成,抑制钙离子聚集、防止钙结石生长,从根本上解决尿路结石的形成,可以安全有效的彻底解决尿路结石;通过将结石溶解成柠檬酸钙、同时促消化和排泄,加速尿酸和结石排出,具有快速溶解尿路结石、促进结石排出的功效,到达治疗尿路结石的效果,可以快速治疗已经形成的尿路结石;利尿速度快,快速减轻憋尿症状,减轻宠物痛苦,加速结石的排出,排石效果迅速;具有慢性利尿作用,柔和的促使尿酸和结石排出,防结石和排结石效果长期有效;本发明可以添加到日常饲料中,随时使用,使用方便;可以促消化和排泄,有利于宠物健康生长。
具体实施方式
为了更好的说明本发明,便于理解本发明的技术方案,本发明的典型但非限制性的实施例如下:
实施例一
一种防尿路结石的饲料添加剂,按重量百分含量由下述组分组成:别嘌呤醇28%、乳酶生40%、柠檬酸镁31%、依他尼酸0.4%、坎利酸钾0.6%
实施例二
一种防尿路结石的饲料添加剂,按重量百分含量由下述组分组成:别嘌呤醇17%、乳酶生48%、柠檬酸镁33%、依他尼酸1%、坎利酸钾1%
实施例三
一种防尿路结石的饲料添加剂,按重量百分含量由下述组分组成:别嘌呤醇26%、乳酶生50%、柠檬酸镁21%、依他尼酸0.5%、坎利酸钾2.5%
实施例四
一种防尿路结石的饲料添加剂,按重量百分含量由下述组分组成:别嘌呤醇21.5%、乳酶生35%、柠檬酸镁40%、依他尼酸0.7%、坎利酸钾2.8%
本发明对宠物猫进行了对比试验,
试验一:选择20只患有有尿路结石病的猫,按照体重、病情和性别比例相似的原则,分成对照组和试验组(每组10只),对照组饲喂基础日粮,试验组饲喂基础日粮+实施例四制备的防尿路结石的饲料添加剂;每只猫每天喂食实施例四制备的防尿路结石的饲料添加剂3g;基础日粮的配方为:酪蛋白50g、奶粉50g、牛肝200g、肉类200g、燕麦300g、食用油50g。
喂食1天后,试验组所有猫的排尿量均明显增加,对照组病情依旧;喂食2天后,试验组所有猫尿频减少,每次排尿量增大,随尿液排出细小颗粒,对照组病情依旧;喂食3天后,试验组所有猫排尿时不需要长时间摆姿势,不再舔私处,情绪稳定,随尿液排出细小颗粒,对照组6只猫病情依旧,另有4只病情恶化,尿中带血,情绪焦虑;喂食5天后,试验组所有猫,完全恢复到正常状态,食量增大,活泼有精神,对照组4只猫病情依旧,4只猫病情严重,尿中血色增多,情绪非常焦虑,另有2只猫病情严重恶化,无法排尿,紧急送医进行导尿。说明本发明具有快速排出结石的功效,并且可以促消化,有利于宠物健康生长。
试验二:选择40只身体健康的猫,按照体重和性别比例相似的原则,分成对照组和试验组(每组20只),对照组饲喂基础日粮,试验组饲喂基础日粮+实施例四制备的防尿路结石的饲料添加剂;每只猫每天喂食实施例四制备的防尿路结石的饲料添加剂2g;基础日粮的配方为:酪蛋白50g、奶粉50g、牛肝100g、肉类400g、燕麦300g、食用油50g、骨粉200g、氯化钙20g。
喂食30天后,试验组所有猫身体健康,无异常,对照组有3只猫出现尿频,尿量少;喂食60天后,试验组所有猫身体健康,食量增大,活泼好动,对照组有5只猫出现尿频,尿量少,另有3只猫尿中带血,情绪焦虑;喂食90天后,试验组所有猫身体健康,食量增大,活泼有精神,皮毛光滑,对照组11只猫出现尿频,尿量少,另有4只病情恶化,尿中带血,情绪焦虑;喂食120天后,试验组所有猫身体健康,食量增大,活泼有精神,皮毛光滑,对照组11只猫出现尿频,尿量少,另有6只病情恶化,尿中血色增多,情绪非常焦虑,另有2只猫病情严重恶化,无法排尿,紧急送医进行导尿。说明本发明具有防止形成尿路结石的功效,并且可以促消化,有利于宠物健康生长。
Claims (2)
1.一种防止结石、快速排结石的药物、组合物、兽药,其特征在于由A项和B项组成,
A项按重量百分含量计由下述组分组成:别嘌呤醇15-30%、乳酶生35-50%、柠檬酸镁20-40%、依他尼酸0.2-1%、坎利酸钾0.5-3%;
B项按重量份由下述组分组成:酪蛋白50g、奶粉50g、牛肝200g、肉类200g、燕麦300g、食用油50g;
将3克A项和 B项混合即可。
2.如权利要求1所述的一一种防止结石、快速排结石的药物、组合物、兽药,其特征在于由A项和B项组成,
A项按重量百分含量计由下述组分组成:别嘌呤醇21.5%、乳酶生35%、柠檬酸镁40%、依他尼酸0.7%、坎利酸钾2.8%;
B项按重量份由下述组分组成:酪蛋白50g、奶粉50g、牛肝200g、肉类200g、燕麦300g、食用油50g;
将3克A项和 B项混合即可。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610434844.6A CN106036135A (zh) | 2014-07-25 | 2014-07-25 | 一种防止结石、快速排结石的药物、组合物、兽药 |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410358293.0A CN104068288B (zh) | 2014-07-25 | 2014-07-25 | 一种防尿路结石的饲料添加剂 |
| CN201610434844.6A CN106036135A (zh) | 2014-07-25 | 2014-07-25 | 一种防止结石、快速排结石的药物、组合物、兽药 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410358293.0A Division CN104068288B (zh) | 2014-07-25 | 2014-07-25 | 一种防尿路结石的饲料添加剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106036135A true CN106036135A (zh) | 2016-10-26 |
Family
ID=51590207
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610434844.6A Pending CN106036135A (zh) | 2014-07-25 | 2014-07-25 | 一种防止结石、快速排结石的药物、组合物、兽药 |
| CN201410358293.0A Expired - Fee Related CN104068288B (zh) | 2014-07-25 | 2014-07-25 | 一种防尿路结石的饲料添加剂 |
| CN201610434849.9A Pending CN105851522A (zh) | 2014-07-25 | 2014-07-25 | 一种防止尿路结石的饲料 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410358293.0A Expired - Fee Related CN104068288B (zh) | 2014-07-25 | 2014-07-25 | 一种防尿路结石的饲料添加剂 |
| CN201610434849.9A Pending CN105851522A (zh) | 2014-07-25 | 2014-07-25 | 一种防止尿路结石的饲料 |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN106036135A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111418558A (zh) * | 2019-09-22 | 2020-07-17 | 山西大学 | 一种消融代谢性泌尿结石动物模型的构建方法 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106819506A (zh) * | 2016-12-29 | 2017-06-13 | 新昌县拜瑞珂生物技术有限公司 | 一种防尿路结石的饲料添加剂 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066352A1 (en) * | 2011-11-04 | 2013-05-10 | Metabolex, Inc. | Methods for treating gout in patient subpopulations |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI280136B (en) * | 2003-05-30 | 2007-05-01 | Lytone Enterprise Inc | Composition containing dipeptide of histidine and alanine for reducing uric acid |
| CN101006996A (zh) * | 2006-01-25 | 2007-08-01 | 盛骝吾 | 一种治疗泌尿系统结石及高尿酸血症的药物及其制备方法 |
| DE102006027794A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Antihypertonie-Kombinationswafer |
| JP5099794B2 (ja) * | 2007-11-27 | 2012-12-19 | アルデア バイオサイエンシーズ インク. | 新規化合物、組成物、及び使用方法 |
| CN101664413A (zh) * | 2008-09-02 | 2010-03-10 | 天津生机集团股份有限公司 | 防治犬猫磷酸铵镁结石的药用保健剂 |
-
2014
- 2014-07-25 CN CN201610434844.6A patent/CN106036135A/zh active Pending
- 2014-07-25 CN CN201410358293.0A patent/CN104068288B/zh not_active Expired - Fee Related
- 2014-07-25 CN CN201610434849.9A patent/CN105851522A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066352A1 (en) * | 2011-11-04 | 2013-05-10 | Metabolex, Inc. | Methods for treating gout in patient subpopulations |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111418558A (zh) * | 2019-09-22 | 2020-07-17 | 山西大学 | 一种消融代谢性泌尿结石动物模型的构建方法 |
| CN111418558B (zh) * | 2019-09-22 | 2021-09-28 | 山西大学 | 一种消融代谢性泌尿结石动物模型的构建方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105851522A (zh) | 2016-08-17 |
| CN104068288B (zh) | 2016-08-24 |
| CN104068288A (zh) | 2014-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101473903B (zh) | 一种中药保健型宠物猫粮、狗粮 | |
| CN108094320B (zh) | 一种母猪模式化饲喂方法及其妊娠期饲料 | |
| CN106689738B (zh) | 一种母子一体化饲养方法 | |
| CN107467381B (zh) | 生产优质滩羊肉的饲料及育肥方法 | |
| CN105614099B (zh) | 一种改善怀孕母猪健康和提高怀孕母猪繁殖性能的功能性清洁日粮 | |
| CN105029447A (zh) | 一种含有活性益生菌的海洋鱼低聚肽粉 | |
| Nourmohammadi et al. | Effect of dietary acidification on some blood parameters and weekly performance of broiler chickens | |
| Samal et al. | Nutritional stretegies to prevent Urolithiasis in Animals. | |
| Valle et al. | Management of chronic diarrhea in an adult horse | |
| JP2023024222A (ja) | 猫用の毛玉ケアペースト | |
| CN105595028A (zh) | 一种防治妊娠期母猪便秘的纯植物发酵饲料 | |
| CN106993715B (zh) | 一种防治对虾白便的饲料 | |
| CN106260534A (zh) | 一种狨猴人工配合饲料 | |
| KR20180056298A (ko) | 광물질과 비타민을 포함하는 반추동물 사료 조성물 | |
| CN100429991C (zh) | 仔猪断奶饲料 | |
| CN106036135A (zh) | 一种防止结石、快速排结石的药物、组合物、兽药 | |
| CN103815199A (zh) | 一种泌乳母猪杂粕型发酵浓缩饲料 | |
| CN106689773A (zh) | 一种雏鸵鸟专用饲料 | |
| CN105724738A (zh) | 一种母猪妊娠期浓缩饲料 | |
| CN103815200B (zh) | 一种妊娠母猪杂粕型发酵浓缩饲料 | |
| WO2006016424A1 (ja) | カルシウム欠乏症予防及び/又は治療剤 | |
| CN117881291A (zh) | 提高饲料摄入量的方法 | |
| CN106819506A (zh) | 一种防尿路结石的饲料添加剂 | |
| CN113397052A (zh) | 一种育肥羔羊双颗粒饲料及其制备方法和应用 | |
| Kan et al. | Feed additives: do they add to animal welfare? An evaluation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161026 |
|
| WD01 | Invention patent application deemed withdrawn after publication |